Specifically, in the RCT and open-label extension by Duboc et al. [21], encompassing 57 French children with DMD (mean age: 11 years; range: 9–13), the proportion with LVEF < 45% after 60 months of follow-up was significantly lower among those treated with ACE inhibitors (perindopril) (initiated at a LVEF > 55%), in some cases administered in combination with β-blockers (agents not reported), compared with no ACE inhibitor treatment (4% vs. 28%, p = 0.02). The gene discussed is ACE; the disease is Duchenne muscular dystrophy.